Grace Therapeutics, Inc. (GRCE) Stock Forecast
GRCE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $5.90 average of analyst targets
- Upside to target
- +212.2% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $1.89 – $5.13
GRCE analyst ratings
2 analystsNumber of analysts at each rating.
GRCE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GRCE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | −$0.21 | −$0.08 | −147.4% | 1 |
| Next quarter (Dec '26) | −$0.21 | −$0.21 | −$0.21 | −$0.19 | −9.3% | 1 |
| Current fiscal year (FY2027) | −$0.76 | −$0.76 | −$0.76 | −$0.66 | −15.7% | 1 |
| Next fiscal year (FY2028) | −$0.64 | −$0.68 | −$0.60 | −$1.67 | +61.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GRCE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Next quarter (Dec '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (FY2028) | $6.8M | $0 | $13.7M | 0.0% | 2 |
GRCE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GRCE revenue: reported and forecast
GRCE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.20 | −$0.18 | −$0.18 | −$0.21 | +1.5% | 0 up · 1 down |
| Next quarter (Dec '26) | −$0.20 | −$0.20 | −$0.18 | −$0.18 | −$0.21 | +1.5% | 0 up · 1 down |
| Current fiscal year (FY2027) | −$0.95 | −$0.95 | −$0.74 | −$0.74 | −$0.76 | −19.8% | 0 up · 1 down |
| Next fiscal year (FY2028) | −$0.79 | −$0.79 | −$0.77 | −$0.77 | −$0.64 | −19.3% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GRCE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GRCE beat in 10 of 12.
What analysts expect from GRCE
2 analysts cover Grace Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.90, 212.2% above the latest close of $1.89. Analysts expect earnings of −$0.76 per share for FY2027, −15.7% from a year earlier. For FY2028 the average estimate is −$0.64 per share on revenue of $6.8 million. Grace Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: GRCE income statement, GRCE key metrics, GRCE chart. See the GRCE stock overview for the latest quote and news.
GRCE forecast FAQ
What is Grace Therapeutics's price target?
The average analyst price target for Grace Therapeutics is $5.90, 212.2% above the latest close of $1.89.
Is Grace Therapeutics a buy, hold or sell?
Of 2 analysts covering Grace Therapeutics, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Grace Therapeutics's EPS forecast?
Analysts forecast −$0.76 per share for FY2027 (range −$0.76 to −$0.76); for FY2028 the estimate is −$0.64.
When does Grace Therapeutics report earnings?
Grace Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Grace Therapeutics usually beat earnings estimates?
Grace Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.